|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Dynavax Technologies (NASDAQ:DVAX), a developer of products to treat allergies, infectious diseases, and chronic inflammatory diseases using proprietary approaches that alter immune system responses. |
|---|---|
| Transferring Party | Rhein Biotech GmbH, a German manufacturer of antigens. |
| Sector | Biopharmaceuticals |
| Date | March 27, 2006 |
| Analysis Dyavax gains ownership of a European Union (EU) GMP-certified vaccine manufacturing facility, control over the production of antigens to support clinical and commercial programs, and a complementary pipeline of vaccine and antiviral products. Deal value --approximately $12m cash; expected to close in 2Q06. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |